IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지

Enhancement of Transduction Efficiency and Antitumor Effects of IL-12N220L-expressing Adenovirus by Co-delivery of DOTAP

  • Youn, Je-In (Division of Molecular and Life Science, Pohang University of Science and Technoloyg) ;
  • Jin, Hyun-Tak (Research Institute, Genexine Co. Ltd.) ;
  • Sung, Young-Chul (Division of Molecular and Life Science, Pohang University of Science and Technoloyg)
  • Published : 2007.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Adenovirus (Ad) vectors have been widely used for many gene therapy applications because of their high transduction ability and broad tropism. However, their utility for cancer gene therapy is limited by their poor transduction into cancer cells lacking the primary receptor, coxsackievirus and adenovirus receptor (CAR). Methods: To achieve CAR-independent gene transfer via Ad, we pretreated Ad with 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) and analyzed their transduction efficiency into cancer cells in vitro and in vivo comparing with the virus alone. Results: Treatment of DOTAP significantly increased adenoviral gene transfer in tumor cells in vitro. Moreover, DOTAP at an optimum dose $(10{\mu}g/ml)$ enhanced IL-12 transgene expression by fivefold in tumor, and twofold in serum after intratumoral injection of adenovirus expressing IL-12N220L (Ad/IL-12N220L). In addition, cotreatment of DOTAP decreased tumor growth rate in the Ad/IL-12N220L-transduced tumor model, finally leading to enhanced survival rate. Conclusion: Our results strongly suggest that DOTAP could be of great utility for improving adenovirus-mediated cancer gene therapy.

Keywords

References

  1. Benihoud K, Yeh P, Perricaudet M: Adenovirus vectors for gene delivery. Curr Opin Biotechnol 10;440-447, 1999 https://doi.org/10.1016/S0958-1669(99)00007-5
  2. St George JA: Gene therapy progress and prospects: adenoviral vectors. Gene Ther 10;1135-1141, 2003 https://doi.org/10.1038/sj.gt.3302071
  3. Seth P: Vector-mediated cancer gene therapy: an overview. Cancer Biol Ther 4;512-517, 2005 https://doi.org/10.4161/cbt.4.5.1705
  4. Yang ZR, Wang HF, Zhao J, Peng YY, Wang J, Guinn BA, Huang LQ: Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy. Cancer Gene Ther 14;599-615, 2007 https://doi.org/10.1038/sj.cgt.7701054
  5. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275;1320-1323, 1997 https://doi.org/10.1126/science.275.5304.1320
  6. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D, Curiel DT: Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 58;5738-5748, 1998
  7. Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP, Wang Z, Hsieh JT: Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 59;325-330, 1999
  8. Cripe TP, Dunphy EJ, Holub AD, Saini A, Vasi NH, Mahller YY, Collins MH, Snyder JD, Krasnykh V, Curiel DT, Wickham TJ, DeGregori J, Bergelson JM, Currier MA: Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res 61;2953-2960, 2001
  9. Persson R, Wohlfart C, Svensson U, Everitt E: Virus-receptor interaction in the adenovirus system: characterization of the positive cooperative binding of virions on HeLa cells. J Virol 54;92-97, 1985
  10. Byk T, Haddada H, Vainchenker W, Louache F: Lipofectamine and related cationic lipids strongly improve adenoviral infection efficiency of primitive human hematopoietic cells. Hum Gene Ther 9;2493-2502, 1998 https://doi.org/10.1089/hum.1998.9.17-2493
  11. Lee SG, Yoon SJ, Kim CD, Kim K, Lim DS, Yeom YI, Sung MW, Heo DS, Kim NK: Enhancement of adenoviral transduction with polycationic liposomes in vivo. Cancer Gene Ther 7;1329-1335, 2000 https://doi.org/10.1038/sj.cgt.0236
  12. Fasbender A, Zabner J, Chillon M, Moninger TO, Puga AP, Davidson BL, Welsh MJ: Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem 272;6479-6489, 1997 https://doi.org/10.1074/jbc.272.10.6479
  13. Toyoda K, Nakane H, Heistad DD: Cationic polymer and lipids augment adenovirus-mediated gene transfer to cerebral arteries in vivo. J Cereb Blood Flow Metab 21;1125-1131, 2001 https://doi.org/10.1038/sj.bmt.1701225
  14. Lanuti M, Kouri CE, Force S, Chang M, Amin K, Xu K, Blair I, Kaiser L, Albelda S: Use of protamine to augment adenovirus-mediated cancer gene therapy. Gene Ther 6;1600-1610, 1999 https://doi.org/10.1038/sj.gt.3300987
  15. Clark PR, Stopeck AT, Brailey JL, Wang Q, McArthur J, Finer MH, Hersh EM: Polycations and cationic lipids enhance adenovirus transduction and transgene expression in tumor cells. Cancer Gene Ther 6;437-446, 1999 https://doi.org/10.1038/sj.cgt.7700074
  16. Lee EM, Hong SH, Lee YJ, Kang YH, Choi KC, Choi SH, Kim IH, Lim SJ: Liposome-complexed adenoviral gene transfer in cancer cells expressing various levels of coxsackievirus and adenovirus receptor. J Cancer Res Clin Oncol 130;169-177, 2004 https://doi.org/10.1007/s00432-003-0521-z
  17. Dodds E, Piper TA, Murphy SJ, Dickson G: Cationic lipids and polymers are able to enhance adenoviral infection of cultured mouse myotubes. J Neurochem 72;2105-2112, 1999 https://doi.org/10.1046/j.1471-4159.1999.0722105.x
  18. Fukuhara H, Hayashi Y, Yamamoto N, Fukui T, Nishikawa M, Mitsudo K, Tohnai I, Ueda M, Mizuno M, Yoshida J: Improvement of transduction efficiency of recombinant adenovirus vector conjugated with cationic liposome for human oral squamous cell carcinoma cell lines. Oral Oncol 39;601-609, 2003 https://doi.org/10.1016/S1368-8375(03)00047-2
  19. Qiu C, De Young MB, Finn A, Dichek DA: Cationic liposomes enhance adenovirus entry via a pathway independent of the fiber receptor and alpha(v)-integrins. Hum Gene Ther 9;507-520, 1998 https://doi.org/10.1089/hum.1998.9.4-507
  20. Bei R, Guptill V, Masuelli L, Kashmiri SV, Muraro R, Frati L, Schlom J, Kantor J: The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice. J Immunother (1997) 21;159-169, 1998 https://doi.org/10.1097/00002371-199805000-00001
  21. Crook K, Stevenson BJ, Dubouchet M, Porteous DJ: Inclusion of cholesterol in DOTAP transfection complexes increases the delivery of DNA to cells in vitro in the presence of serum. Gene Ther 5;137-143, 1998 https://doi.org/10.1038/sj.gt.3300554
  22. Lardans V, Boulo V, Duclermortier P, Serra E, Mialhe E, Capron A, Dissous C: DNA transfer in a Biomphalaria glabrata embryonic cell line by DOTAP lipofection. Parasitol Res 82; 574-576, 1996 https://doi.org/10.1007/s004360050166
  23. Yotnda P, Chen DH, Chiu W, Piedra PA, Davis A, Templeton NS, Brenner MK: Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther 5;233-241, 2002 https://doi.org/10.1006/mthe.2002.0545
  24. Ha SJ, Chang J, Song MK, Suh YS, Jin HT, Lee CH, Nam GH, Choi G, Choi KY, Lee SH, Kim WB, Sung YC: Engineering N-glycosylation mutations in IL-12 enhances sustained cytotoxic T lymphocyte responses for DNA immunization. Nat Biotechnol 20;381-386, 2002 https://doi.org/10.1038/nbt0402-381
  25. Jee YS, Lee SG, Lee JC, Kim MJ, Lee JJ, Kim DY, Park SW, Sung MW, Heo DS: Reduced expression of coxsackievirus and adenovirus receptor (CAR) in tumor tissue compared to normal epithelium in head and neck squamous cell carcinoma patients. Anticancer Res 22;2629-2634, 2002
  26. Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, Curiel DT, Douglas JT: The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 38;1917-1926, 2002 https://doi.org/10.1016/S0959-8049(02)00131-4
  27. Mack CA, Song WR, Carpenter H, Wickham TJ, Kovesdi I, Harvey BG, Magovern CJ, Isom OW, Rosengart T, Falck-Pedersen E, Hackett NR, Crystal RG, Mastrangeli A: Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 8;99-109, 1997 https://doi.org/10.1089/hum.1997.8.1-99
  28. Loewi G, Meyer K: The acid mucopolysaccharides of embryonic skin. Biochim Biophys Acta 27;453-456, 1958 https://doi.org/10.1016/0006-3002(58)90371-8
  29. Yolken RH, Willoughby R, Wee SB, Miskuff R, Vonderfecht S: Sialic acid glycoproteins inhibit in vitro and in vivo replication of rotaviruses. J Clin Invest 79;148-154, 1987 https://doi.org/10.1172/JCI112775
  30. Wilcox WC, Ginsberg HS: Purification and immunological characterization of types 4 and 5 adenovirus-soluble antigens. Proc Natl Acad Sci U S A 47;512-526, 1961